Live Breaking News & Updates on Parp Inhibitorsa New Frontier In The Battle Against Cervical Cancer Selectscience Research

Editorial Article: PARP inhibitors: A new frontier in the battle against cervical cancer
Dr. Santu Saha shares his team’s groundbreaking work to develop improved cancer treatments to avoid the potential side effects of chemotherapy
05 Feb 2021
Dr. Santu Saha, Newton International Fellow of the Academy of Medical Sciences, Newcastle University
In this exclusive interview, we hear from Dr. Santu Saha about his ongoing research into effective new ways to treat cervical cancer. Dr. Saha, a Newton International fellow of the Academy of Medical Sciences working at Newcastle University, U.K., outlines how a DNA damage response pathway inhibitor, i.e. poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi), can be used to serve as reliable cancer therapies to ameliorate cisplatin toxicity whilst also targeting hypoxic tumor cells for the treatment of cervical and other cancers, where cisplatin-based chemo-radiotherapy is the standard treatment.  ....

Santu Saha , Corning Elplasia , Newcastle University , Newton International , Academy Of Medical Sciences , Editorial Article , Newton International Fellow , Medical Sciences , Rev Drug , Natl Cancer , Parp Inhibitorsa New Frontier In The Battle Against Cervical Cancer Selectscience Research , Cancer Treatment , சந்து சஹா , நியூகேஸில் பல்கலைக்கழகம் , நியூட்டன் சர்வதேச , கலைக்கழகம் ஆஃப் மருத்துவ அறிவியல் , தலையங்கம் கட்டுரை , நியூட்டன் சர்வதேச சக , மருத்துவ அறிவியல் , ரெவ் மருந்து , நட்டில் புற்றுநோய் , புற்றுநோய் சிகிச்சை ,